Skip to main content
. 2020 Dec 8;18(3):170–186. doi: 10.1038/s41571-020-00447-z

Fig. 2. Clinical pathway for IDH-mutant gliomas.

Fig. 2

KPS, Karnofsky performance status; PCV, procarbazine, lomustine and vincristine.